Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents

Waweru, Catherine; Kaur, Simarjeet; Sharma, Sheetal

doi:10.1080/03007995.2020.1784120

Cited by 14 publications

(19 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many molecular therapeutic targets for hematological malignancies have been discovered with the deepening of molecular biology research and technological advancement (9,(17)(18)(19)(20). The drugs developed in this way delay the progression of the disease to a significant extent and significantly improve the patient's disease-free survival (DFS) and quality of life (21)(22)(23). However, some authors believe it has not helped complete the eradication of tumors (9).…”

Section: Discussionmentioning

confidence: 99%

A bibliometric analysis of the research on hematological tumor microenvironment

Peng¹,

Du²,

Wang³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: In recent years, the incidence of hematological tumors has increased. The tumor microenvironment (TME) is the local biological environment in the process of tumor occurrence and development and is closely related to hematological malignancies, including lymphoma and leukemia. This study aims to conduct a bibliometric analysis of the research on the hematological TME, reflect the general situation of the research in this field, and remind the focus of future research.Methods: Search the Science Citation Index Expanded (SCI-E) database on the Web of Science Core Collection (WOSCC). Use subject terms to search tumor microenvironment; the limited search subject is Hematology, and the time range is from 1990 to July 18, 2021. Use CiteSpace software to analyze the number of annual papers published, the number of citations, the distribution of disciplines, the distribution of countries/institutions, the distribution of authors, the distribution of journals, and the frequency of use of keywords and its trend of change.Results: There were 1,992 related research articles cited 77,213 times. The top 5 countries with the number of published papers in this field are: the United States, Italy, China, Germany, and the United Kingdom; the top 5 centrally ranked countries are the United States, Italy, Spain, France, and Japan.Literature and cooperation are mainly from the United States. The top three researchers with several published papers are Anderson KC, Ansell SM, and Gascoyne RD. Their centrality scores are all low, with only 5 researchers reaching above 0.01, and there is less collaboration between the authors. Highquality papers are from Blood, Cancer Res, P Natl Acad Sci USA, and Nature. Keyword analysis shows that immunotherapy is the current focus of research in this field. Conclusions:The research on the microenvironment of hematological malignancies is rapidly developing.At present, the main research focus is on targeted immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

A bibliometric analysis of the research on hematological tumor microenvironment

Peng¹,

Du²,

Wang³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

show abstract

“…Patients with CLL score poorly in most domains of the EORTC QLQ-C30 compared with healthy controls, particularly that of fatigue [4,7,8]. Quality of life (QoL) may be further affected by the emotional burden of living with a chronic disease, as indicated by impairment of emotional functioning QoL domains and reports of greater health-related worries [4,9,10]. Chemoimmunotherapy (CIT) has been the traditional treatment for CLL [3] but this does not consistently improve HRQoL; on the contrary, negative impact on HRQoL has been reported, likely resulting from treatment-related toxicities [7,10,11].…”

Section: Original Articlementioning

confidence: 95%

“…Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial Introduction Chronic lymphocytic leukemia (CLL) accounts for approximately 30% of all leukemias, with a median age at diagnosis of 67 years and a 5-year relative survival of >80% [1][2][3]. While a 'watch and wait' approach is recommended for asymptomatic disease, therapy is indicated for those with symptomatic CLL; however, it is not curative [4,5].…”

Section: Original Articlementioning

confidence: 99%

“…CLL and its associated symptomology can negatively impact several aspects of health-related quality of life (HRQoL) [4,6]. Patients with CLL report significantly impaired global health status (GHS), as recorded by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, a self-report questionnaire validated for use in oncology studies) [7].…”

Section: Original Articlementioning

confidence: 99%

“…Patients with CLL report significantly impaired global health status (GHS), as recorded by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, a self-report questionnaire validated for use in oncology studies) [7]. Patients with CLL score poorly in most domains of the EORTC QLQ-C30 compared with healthy controls, particularly that of fatigue [4,7,8]. Quality of life (QoL) may be further affected by the emotional burden of living with a chronic disease, as indicated by impairment of emotional functioning QoL domains and reports of greater health-related worries [4,9,10].…”

Section: Original Articlementioning

confidence: 99%

See 2 more Smart Citations

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

Cochrane

Enrico

Gómez‐Almaguer

et al. 2021

Leukemia & Lymphoma

View full text Add to dashboard Cite

Venetoclax, a potent B-cell lymphoma-2 (BCL-2) inhibitor, has demonstrated clinical efficacy in chronic lymphocytic leukemia (CLL). VENICE II is an open-label, single-arm, phase 3b study (NCT02980731) evaluating the impact of venetoclax monotherapy (400 mg once daily) for 2 years on health-related quality of life (HRQoL) of patients with relapsed/refractory CLL. The primary endpoint was mean change in the global health status (GHS)/quality of life (QoL) subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) from baseline to Week 48. Overall, 210 patients received !1 dose of venetoclax; median treatment duration was 67.4 weeks. The primary endpoint was met with mean improvement of þ9.3 points (n ¼ 156, 95% confidence interval 6.1-12.5; p¼.004) in GHS/QoL. At Week 48, clinically meaningful improvements were observed for role functioning, fatigue, and insomnia domains of EORTC QLQ-C30, suggesting venetoclax monotherapy has a positive impact on HRQoL. No new safety signals were reported.

show abstract

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

Sportoletti,

Laurenti,

Chiarenza

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) therapies differ in efficacy, side effects, route, frequency, and duration of administration. We assessed patient preferences for treatment attributes and evaluated associations with disease stage, treatment line, and socio‐demographic characteristics in a cross sectional, observational study conducted at 16 Italian hematology centers. Study visits occurred between February and July 2020; 401 adult patients with CLL (201 Watch and Wait (W&W), 200 treated) participated in a discrete choice experiment (DCE), composed of 8 choices between pairs of treatment profiles with different levels of 5 attributes of currently available CLL treatments (length of response, route and duration of administration, risk of side effects including diarrhea, infections, or organ damage). Health‐related quality of life was assessed with the EQ‐5D‐5L, EORTC QLQ‐C30 and QLQ CLL‐16. Previously treated patients had longer disease duration (7 vs. 5 years), higher prevalence of serious comorbidities (45.5% vs. 36.2%) and high‐risk molecular markers (unmutated IGHV 55.6% vs. 17.1%; TP53 mutation 15.2% vs. 4.0%). Health‐related quality of life scores were similar between groups. In the DCE, W&W patients rated “possible occurrence of infections” highest (relative importance [RI] = 36.2%), followed by “treatment and relevant duration” (RI = 28.0%) and “progression‐free survival (PFS)” (RI = 16.9%). Previously treated patients rated “treatment and relevant duration” highest (RI = 33.3%), followed by “possible occurrence of infections” (RI = 28.8%), “possible occurrence of organ damage” (RI = 19.4%), and “PFS” (RI = 9.8%). Concern over infection was rated highest overall; unexpectedly PFS was not among the most important criteria in either group, suggesting that the first COVID‐19 pandemic wave may have influenced patient preferences and concerns about CLL therapy options.

show abstract

Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents

Cited by 14 publications

References 51 publications

A bibliometric analysis of the research on hematological tumor microenvironment

A bibliometric analysis of the research on hematological tumor microenvironment

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study

Contact Info

Product

Resources

About